42 related articles for article (PubMed ID: 34127506)
1. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.
Parikh SA; Achenbach SJ; Call TG; Rabe KG; Ding W; Leis JF; Kenderian SS; Chanan-Khan AA; Koehler AB; Schwager SM; Muchtar E; Fonder AL; McCullough KB; Nedved AN; Smith MD; Slager SL; Kay NE; Finnes HD; Shanafelt TD
Cancer Med; 2020 May; 9(10):3390-3399. PubMed ID: 32187452
[TBL] [Abstract][Full Text] [Related]
2. A CAPTIVATEing Analysis for Higher-Risk CLL.
Rogers KA
Clin Cancer Res; 2023 Jul; 29(14):2561-2562. PubMed ID: 37289004
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia.
Czogalla J; Schliffke S; Lu S; Schwerk M; Petereit H; Zhang T; Liu S; Dumoulin B; Gies S; Wu G; Hänzelmann S; Bode M; Grahammer F; Gödel M; Voigtländer M; Butt L; Bokemeyer C; Bergmann C; Benzing T; Wiech T; Puelles VG; Huber TB
Kidney Int; 2024 Apr; 105(4):877-881. PubMed ID: 38336226
[No Abstract] [Full Text] [Related]
4. An effective treatment and suspicious adverse reaction to Ibrutinib in a patient diagnosed with splenic B-cell lymphoma/leukaemia with prominent nucleoli: A first case report.
Shen MX; Li FL; Luo XS; Wang ZM
Medicine (Baltimore); 2023 Dec; 102(52):e36022. PubMed ID: 38206706
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia with deletion 17p: An Indian scenario.
Gogia A; Gupta R; Kumar L; Sharma A; Soni L
South Asian J Cancer; 2019; 8(1):40. PubMed ID: 30766851
[No Abstract] [Full Text] [Related]
6. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes in Patients with Multi-Hit
Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Allan JN; Shanafelt T; Wiestner A; Moreno C; O'Brien SM; Li J; Krigsfeld G; Dean JP; Ahn IE
Br J Haematol; 2022 Feb; 196(4):947-953. PubMed ID: 34865212
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
Sivina M; Kim E; Wierda WG; Ferrajoli A; Jain N; Thompson P; Kantarjian H; Keating M; Burger JA
Blood; 2021 Dec; 138(24):2589-2592. PubMed ID: 34521099
[No Abstract] [Full Text] [Related]
10. Deep targeted sequencing of
Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
[TBL] [Abstract][Full Text] [Related]
11. Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
Visentin A; Mauro FR; Cibien F; Vitale C; Reda G; Fresa A; Ciolli S; Pietrasanta D; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Scarfò L; Sportoletti P; Pravato S; Piazza F; Coscia M; Laurenti L; Molica S; Foà R; Cuneo A; Trentin L
Am J Hematol; 2022 Mar; 97(3):E95-E99. PubMed ID: 34904743
[No Abstract] [Full Text] [Related]
12.
Bomben R; Zucchetto A; Gentile M; Gattei V
Clin Cancer Res; 2021 Aug; 27(16):4462-4464. PubMed ID: 34127506
[TBL] [Abstract][Full Text] [Related]
13.
Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
